Integrating DEM-TACE in mCRC: Clinical evidence, patient selection, and procedural excellence

Thursday, February 19, 2026, 17:00-18:30 CET

Programme | Faculty | Free registration

Join us for a live, expert-led webinar that brings evidence from the largest real-world observational study on DEM-TACE for metastatic colorectal cancer (mCRC) directly to your practice. Drawing on the pan-European, prospective CIREL registry and other pivotal studies, this session will highlight how irinotecan DEM-TACE can achieve tumour response with low toxicity, maintain quality of life, and deliver encouraging long-term outcomes both in consolidation settings and in chemo-refractory patients. Participants will gain a clear understanding of the clinical evidence and the key prognostic factors that define the “right patient” for TACE, including tumour burden, prior therapies, and lesion size. Practical considerations that differentiate DEM-TACE from selective internal radiation therapy (SIRT) in everyday decision-making will also be addressed.

This CIRSE webinar, conducted in collaboration with Terumo Interventional Systems, combines scientific data, patient-selection guidance, and hands-on procedural insights to support the integration of DEM-TACE into mCRC treatment pathways. The expert faculty will walk through peri-procedural management strategies and pain-control protocols essential for maintaining HRQoL and preventing treatment discontinuation, illustrated through real CIREL cases. We invite you to join the session live and be part of shaping the next steps in evidence-based, patient-centered care for colorectal liver metastases.

Learning objectives

1. Understand the key findings of the study on irinotecan DEM-TACE for colorectal liver metastases, including its impact on symptom burden, toxicity, overall survival, hepatic PFS, and patient quality of life.
2. Recognize the prognostic factors that help identify suitable candidates for DEM-TACE, such as tumour burden, number of prior systemic therapies, and lesion size.
3. Learn the importance of peri-procedural pain management protocols to preserve quality of life and reduce the risk of treatment discontinuation.
4. Clarify when to use DEM-TACE versus SIRT in mCRC patients by considering patient characteristics, access, and cost-related factors.

Programme

Introduction by the moderator
Philippe Pereira (Heilbronn/DE)

Exploring the role of DEM-TACE in colorectal liver metastases
Julien Taieb (Paris/FR)

Smart selection in practice: Identifying the right patient for optimal DEM-TACE outcomes
Geert Maleux (Leuven/BE), Dirk Arnold (Hamburg/DE)

DEM-TACE patients’ journey in colorectal liver metastases
Roberto Iezzi (Rome/IT), Aleksander Gjoreski (Skopje/MK)

Discussion and Q&A
Panel discussion

Conclusion from moderator
Dirk Arnold (Hamburg/DE)

Faculty

Moderators

Speakers

Join free of charge!

Access to this webinar is available free of charge to all interested parties. All you need is your CIRSE login details. Don’t have a CIRSE account yet? Not to worry! It only takes two minutes to set up a new account which will enable you to register.